Your Messages Inbox
Your Article Summary
See Latest ArticlesProtox Announces Positive Phase 2 BPH Results
Protox Therapeutics , 11/25/08
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, announced positive data from its Phase 2 study of PRX302 in patients with benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects over 50 million men worldwide. The study results indicate that PRX302 provided significant symptomatic relief while maintaining an excellent safety profile in men with moderate to severe BPH.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Article Search
Sponsor